EIO Biomedical is a privately held Israeli start-up company, committed to the development of a proprietary medical device for the reduction of post-surgical adhesions. EIO is approaching a multi-billion dollars unmet market need. Located in Nazareth, Israel, the company secured financing from NGT3 VC (www.ngt3vc.com ) and the Israeli Government. EIO Biomedical is now a clinical stage company! We have initiated our first-in-human clinical trial of our FuseX system for the prevention of surgical adhesions on schedule. 12 patients in all will be recruited for this double blind trial. Results will be posted on our website, www.eiobio.com. Surgical adhesions are one of the most pressing problems in general surgery today, leading to a variety of post-operative complications, from life-threatening bowel obstruction up to chronic and debilitating pain. According to The Lancet, 35% of people who have had abdominal surgery will require resurgery twice within 10 years, 22% within 1 year (Lancet. 1999; 353(9163):1476-80). Surgical adhesions are a major unmet need, as current solutions have failed to significantly improve these complications. EIO Biomedical is working on a novel medical device that will issue a sprayable adhesion barrier capable of actively reducing the extent of the problem. Our proprietary device and bio-process converts a single unit of blood plasma for infusion, to generate a unique enzymatic combination that actively reduces the adhesion formation process. A disposable kit provided with the device ensures that each patient receives a safe and sterile product. We see a significant reduction of peritoneal adhesions in both rat and pig models. EIO Biomedical enjoys strong and wide intellectual property coverage, with at least two patent applications protecting our composition and proprietary system.